Skip to main content
Premium Trial:

Request an Annual Quote

Buyers Line Up as EKF Mulls Sale of POC Dx Business

NEW YORK (GenomeWeb) – EKF Diagnostics today announced that it has received two new proposals regarding the sale of its point-of-care (POC) diagnostics business.

EKF said in a statement that it has received a second non-binding preliminary offer of $115 million to $125 million in cash for its POC diagnostics unit from an undisclosed third party.

In a separate statement, the firm said it has received a third non-binding preliminary proposal for the POC diagnostics business from Chinese firm Jinjing Group that may or may not lead to an offer.

The deals would not include EKF's clinical chemistry or molecular diagnostics businesses.

The Cardiff, UK-based firm announced the potential sale of its POC diagnostics business as a result of a strategic review initiated by its board in April. An undisclosed buyer has offered $110 million for the POC diagnostics business.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.